Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $17,293,477.89 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 27,833 shares of Medpace stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $621.33, for a total value of $17,293,477.89. Following the completion of the sale, the chief executive officer owned 389,456 shares of the company’s stock, valued at $241,980,696.48. This trade represents a 6.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Medpace Price Performance

NASDAQ MEDP opened at $618.88 on Monday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The company has a 50-day moving average of $594.65 and a 200-day moving average of $516.25. The company has a market cap of $17.27 billion, a P/E ratio of 36.28, a P/E/G ratio of 2.76 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period last year, the company earned $3.10 earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research analyst reports. Truist Financial lifted their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. TD Cowen lifted their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $595.20.

Hedge Funds Weigh In On Medpace

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Medpace during the second quarter worth $1,323,047,000. Madison Asset Management LLC acquired a new position in shares of Medpace in the 2nd quarter worth approximately $128,956,000. Bank of America Corp DE acquired a new stake in shares of Medpace during the second quarter worth $116,891,000. American Capital Management Inc. acquired a new stake in Medpace during the second quarter worth about $111,329,000. Finally, Franklin Resources Inc. lifted its holdings in shares of Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after purchasing an additional 183,645 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.